In ₹ Crore except Per Share Latest Annual | KREBSBIO FY26 | ALPA FY26 | BALPHARMA FY26 | VINEETLAB FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | ◆ 9.27× | 26.71× | 36.00× | 26.71× | |
| P/B | — | ◆ 0.70× | 2.04× | 1.52× | 1.52× | |
| EV/EBITDA | ◆ -65.36× | -0.70× | 10.13× | 11.53× | 10.13× -745% | |
| Market Cap | ₹132 Cr | ₹131 Cr | ₹168 Cr | ₹69.2 Cr | ₹131 Cr +1% | |
| Growth | ||||||
| Revenue CAGR 3Y | -23.07% | ◆ 4.61% | 0.81% | -34.59% | 0.81% -2948% | |
| Revenue CAGR 5Y | -15.07% | 1.64% | ◆ 4.46% | -24.58% | 1.64% -1019% | |
| Net Income CAGR 3Y | — | 3.80% | ◆ 34.14% | 8.59% | 8.59% | |
| Revenue YoY (latest Q) | 27.42% | 25.22% | ◆ 34.53% | 34.21% | 34.21% -20% | |
| Net Income YoY (latest Q) | 53.33% | -91.67% | ◆ 445.66% | 111.58% | 111.58% -52% | |
| Profitability | ||||||
| EBITDA Margin | -22.97% | 3.11% | 10.24% | ◆ 14.27% | 10.24% -324% | |
| Net Income Margin | -71.35% | ◆ 13.35% | 2.03% | 2.70% | 2.70% -2743% | |
| Return on Common Equity | ◆ 10.40% | 7.58% | 7.64% | 3.52% | 7.58% +37% | |
| Return on Capital Employed | -23.66% | 0.63% | ◆ 16.49% | 10.55% | 10.55% -324% | |
| Return on Assets | -10.37% | ◆ 5.83% | 1.68% | 1.29% | 1.68% -717% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ -1.38× | 0.01× | 1.94× | 0.99× | 0.99× -239% | |
| Interest Coverage | -1.68× | ◆ 4.65× | 1.24× | 1.24× | 1.24× -235% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹23.7 Cr | ₹106 Cr | ₹312 Cr | ₹59.4 Cr | ₹106 Cr -78% | |
| Net Income | −₹16.9 Cr | ₹14.1 Cr | ₹6.3 Cr | ₹1.6 Cr | ₹6.3 Cr -368% | |
| Total Assets | ₹163 Cr | ₹242 Cr | ₹376 Cr | ₹125 Cr | ₹242 Cr -33% | |
| EPS | ₹-7.85 | ₹6.71 | ₹3.95 | ₹1 | ₹3.95 -299% | |
| Book Value per Share | ₹-75.49 | ₹88.53 | ₹51.66 | ₹23.74 | ₹51.66 -246% | |